A2M, alpha-2-macroglobulin, 2

N. diseases: 147; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.500 Biomarker disease HPO
CUI: C3279661
Disease: alpha-2-Macroglobulin Deficiency
alpha-2-Macroglobulin Deficiency
0.310 Biomarker disease CTD_human
Neurofibrillary degeneration (morphologic abnormality)
0.100 Biomarker phenotype HPO
CUI: C0242422
Disease: Parkinsonian Disorders
Parkinsonian Disorders
0.100 Biomarker group HPO
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease HPO
ALZHEIMER DISEASE, SUSCEPTIBILITY TO
0.100 SusceptibilityMutation phenotype CLINVAR
CUI: C1865903
Disease: Long-tract signs
Long-tract signs
0.100 Biomarker phenotype HPO
CUI: C4703620
Disease: Decreased level of GABA in serum
Decreased level of GABA in serum
0.100 Biomarker phenotype HPO
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis
0.040 Biomarker disease BEFREE These results suggest a possible alteration in the carbohydrate moiety of alpha 2-macroglobulin in cystic fibrosis, presumably due to a defective posttranslational process. 91457 1979
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis
0.040 Biomarker disease BEFREE Normal two-dimensional gel electrophoresis of alpha-2-macroglobulin in cystic fibrosis. 6155781 1980
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis
0.040 Biomarker disease BEFREE Normal subunit cleavage of alpha-2-macroglobulin in cystic fibrosis. 6153300 1980
CUI: C0013080
Disease: Down Syndrome
Down Syndrome
0.010 Biomarker disease BEFREE The mean alpha 2-macroglobulin concentrations were investigated and it was shown that PiMZ phenotypes had a higher concentration, 2.67 +/- 0.27 g/l (newborns) and 2.74 +/- 0.32 g/l (Down's syndrome), in comparison with PiMS, PiSS, and PiMM. 6157025 1980
CUI: C4521042
Disease: Complete Trisomy 21 Syndrome
Complete Trisomy 21 Syndrome
0.010 Biomarker disease BEFREE The mean alpha 2-macroglobulin concentrations were investigated and it was shown that PiMZ phenotypes had a higher concentration, 2.67 +/- 0.27 g/l (newborns) and 2.74 +/- 0.32 g/l (Down's syndrome), in comparison with PiMS, PiSS, and PiMM. 6157025 1980
CUI: C0221757
Disease: alpha 1-Antitrypsin Deficiency
alpha 1-Antitrypsin Deficiency
0.020 Biomarker disease BEFREE These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present. 6169740 1981
CUI: C0024115
Disease: Lung diseases
Lung diseases
0.320 Biomarker group BEFREE The highest alpha 2-macroglobulin concentrations were found in the PI Q0 patients (5 with emphysema, 2 with no lung disease), and these patients had almost no circulating alpha 1-antitrypsin. 6189643 1983
CUI: C0034067
Disease: Pulmonary Emphysema
Pulmonary Emphysema
0.020 Biomarker disease BEFREE Raised concentrations of serum alpha 2-macroglobulin were not due to emphysema: 86 patients with emphysema, of PI type M, and the normal control subjects had similar average concentrations of alpha 2-macroglobulin. 6189643 1983
CUI: C0221757
Disease: alpha 1-Antitrypsin Deficiency
alpha 1-Antitrypsin Deficiency
0.020 Biomarker disease BEFREE alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency. 6189643 1983
CUI: C0600260
Disease: Lung Diseases, Obstructive
Lung Diseases, Obstructive
0.010 Biomarker group BEFREE alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency. 6189643 1983
CUI: C0021368
Disease: Inflammation
Inflammation
0.200 Biomarker phenotype RGD Prostaglandin E1, a mediator of inflammation, was investigated for its effects on serum acute phase proteins, alpha 2 macroglobulin (alpha 2M). 6202298 1984
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis
0.040 Biomarker disease BEFREE alpha 2-Macroglobulin (alpha 2M) is a major plasma protease inhibitor that has been studied because of its suggested role in the pathology of cystic fibrosis (CF). 6208528 1984
CUI: C0600327
Disease: Toxic Shock Syndrome
Toxic Shock Syndrome
0.200 Therapeutic disease RGD Alpha 2 macroglobulin of the rat, an acute phase protein, mitigates the early course of endotoxin shock. 2424486 1986
CUI: C0011570
Disease: Mental Depression
Mental Depression
0.300 Biomarker disease PSYGENET CF heterozygotes shared the decrease of alpha 1-lipoprotein with the patients while exhibiting small but significant depressions of alpha 2-macroglobulin and IgG. 2432615 1987
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.300 Biomarker disease PSYGENET Protein abnormalities in adult respiratory distress syndrome, tuberculosis, and cystic fibrosis sera. 2432615 1987
CUI: C0015967
Disease: Fever
Fever
0.200 Biomarker phenotype RGD Fever was continuously recorded and 24 h after induction acute phase reactant (APR) response was measured as indicated by the rise of alpha-macrofetoprotein (alpha M FP, alpha 2 macroglobulin of the rat).Controls received 0.9% saline i.c.v. 2460123 1988
CUI: C0005779
Disease: Blood Coagulation Disorders
Blood Coagulation Disorders
0.010 GeneticVariation group BEFREE A heritable elevation in alpha 2-macroglobulin (alpha 2M) was identified in a 9-year-old girl with a severe bleeding tendency and activated partial thromboplastin time (APTT) prolonged to 49.1 sec (normal 27-38) as well as recalcification time prolonged to 438 sec (less than 180). 2460968 1988